Core Viewpoint - The Trump administration has advised pregnant women against taking acetaminophen, the active ingredient in Tylenol, due to potential links to autism, while the FDA is updating product labels to reflect this concern [1][2][3] Group 1: FDA and Drug Approval - The FDA is beginning the process of updating the label for Tylenol and similar products to indicate a possible association between acetaminophen use during pregnancy and increased risk of neurological conditions like autism [2] - The FDA has communicated to doctors that while studies suggest an association between acetaminophen and autism, a causal relationship has not been established, and there are conflicting studies in the scientific literature [3] - The FDA is also moving to approve an older GSK drug for treating autism symptoms, which has shown some promise in non-verbal patients, although the studies are small and not widely beneficial [4][5] Group 2: Industry Response and Market Reaction - Ken View has been actively pushing back against claims linking Tylenol to autism, asserting that no scientific evidence supports this connection [7] - The medical community, including organizations like the American College of Obstetrics and Gynecology and the Society for Maternal Fetal Medicine, continues to support the use of acetaminophen during pregnancy, indicating a lack of consensus on the issue [8][9] - Despite the controversy, Ken View shares have seen a rebound, suggesting investor confidence remains strong amid the political discourse surrounding the drug [11]

Group 1 - Kenvue's stock experienced a decline of approximately 7.5% yesterday, followed by a pre-market rebound of over 6%, reaching $18.02 [1] - President Trump warned pregnant women against using Tylenol, citing a potential link between acetaminophen and autism, despite the lack of widely accepted scientific evidence [1] - Kenvue issued a statement asserting confidence in independent and reliable scientific evidence that acetaminophen does not cause autism, strongly opposing contrary claims [1]

Core Viewpoint - President Trump warns pregnant women to avoid Tylenol, citing a potential link between acetaminophen and autism, despite a lack of widely accepted scientific evidence supporting this claim [1] Group 1: Government Actions and Statements - The U.S. government plans to modify drug safety labels and launch a nationwide public health campaign regarding acetaminophen use during pregnancy [1] - The FDA has stated that it has not found clear evidence that appropriate use of acetaminophen during pregnancy leads to adverse pregnancy, birth, or developmental outcomes [4][6] Group 2: Scientific Community's Response - Various professional organizations, including the American College of Obstetricians and Gynecologists, argue against discouraging the use of acetaminophen due to its benefits, especially since it is often the only recommended antipyretic for pregnant women [4] - A large-scale study published in 2024 found no increased risk of autism in children whose mothers used acetaminophen during pregnancy [3] Group 3: Legal Context - Prior to Trump's warning, numerous lawsuits claimed that exposure to Tylenol during pregnancy led to autism in children, but a judge dismissed these claims, citing flawed scientific evidence [5] - The legal debate continues, with appeals expected later this year in Manhattan, and the Department of Health and Human Services' statements may influence the court's considerations [5][6]